UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019450
Receipt number R000022406
Scientific Title A Randomized, Double-blind, Placebo-Controlled, Parallel Group Comparison Study on the Effects of Daily Ingestion of Isoflavone -Rich Soybean, "Yukipirika" on the Improvement of Bone Metabolism and Menopausal Symptoms
Date of disclosure of the study information 2015/10/23
Last modified on 2017/10/10 08:52:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Randomized, Double-blind, Placebo-Controlled, Parallel Group Comparison Study on the Effects of Daily Ingestion of Isoflavone -Rich Soybean, "Yukipirika" on the Improvement of Bone Metabolism and Menopausal Symptoms

Acronym

The Effect of Daily Ingestion of the Soybean on the Improvement of Bone Metabolism and Menopausal Symptoms

Scientific Title

A Randomized, Double-blind, Placebo-Controlled, Parallel Group Comparison Study on the Effects of Daily Ingestion of Isoflavone -Rich Soybean, "Yukipirika" on the Improvement of Bone Metabolism and Menopausal Symptoms

Scientific Title:Acronym

The Effect of Daily Ingestion of the Soybean on the Improvement of Bone Metabolism and Menopausal Symptoms

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prove clinical benefits of daily ingestion of isoflavone -rich soybean, "Yukipirika" on bone metabolism and menopausal symptoms for 8 weeks.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Simplified Menopausal Index, urinary NTx, urinary DPyr, serum TRACP-5b at 4 and 8 weeks after ingestion of test meals.

Key secondary outcomes

TC,LDL-C,HDL-C,TG, arteriosclerosis index, E2, FSH,TIBC,UIBC, conditions of skin and hair, functions of joints, VAS scores of bowel movements, BW,BMI and BFR


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Ingestion of 8.5g of "Yukipirika" soybean flakes daily for 8 weeks.

Interventions/Control_2

Ingestion of 8.5g of "Fukuyutaka" soybean flakes daily for 8 weeks.

Interventions/Control_3

Ingestion of 8.5g of wheat flakes daily for 8 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

45 years-old <=

Age-upper limit

65 years-old >

Gender

Female

Key inclusion criteria

1. Subjects who have subjective symptoms of menopause.
2. Subjects whose serum TRACP-5b is >=309 mU/dl and <=760mU/dl.
3. Subjects who agree to participate in the current study with a written informed consent.

Key exclusion criteria

1. Subjects who are under treatment and medication for menopausal symptoms, osteoporosis and thyroid disease.
2. Subjects who are under treatment and medication for psychiatric disorders.
3. Subjects who are considered to have secondary osteoporosis (due to endocrine disorders, continuous use of steroids, etc.).
4. Subjects whose urinary productivity of equol is low.
5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, or gastrointestinal diseases, or affected with infectious diseases which are required to report to the authorities.
6. Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
7. Subjects with unusually high and/or low blood pressure or abnormal hematological data.
8. Subjects with serious anemia.
9. Subjects who are at risk of having allergic reactions to drugs or foods (especially soybean and wheat).
10. Subjects who regularly take medicine, functional foods and/or supplements (isoflavone, daidzein, genistein, glycitein, equol, pycnogeno, onion, maca, etc.) which would improve menopausal symptoms.
11. Subjects who regularly take medicine, functional foods and/or supplements (isoflavone, calcium, magnesium, CBP, MBP, vitamin D, etc.) which would affect the bone metabolism.
12. Heavy smokers, alcohol addicts or subjects with irregular lifestyle
13. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study.
14. Subjects who participate in other clinical trials within the last one month prior to the this study.
15. Any other medical reasons judged by the principal investigator.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Prof. Jun NISHIHIRA, M.D., Ph.D.

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code


Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

nishihira@do-johodai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Dir. Prof. Jun NISHIHIRA, M.D., Ph.D.

Organization

Hokkaido Information University

Division name

Center of Health Information Science

Zip code


Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

nishihira@do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

Northern Advancement Center for Science & Technology

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター (北海道)


Other administrative information

Date of disclosure of the study information

2015 Year 10 Month 23 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.ffhdj.com/index.php/ffhd/article/view/359

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2015 Year 09 Month 30 Day

Date of IRB


Anticipated trial start date

2015 Year 11 Month 19 Day

Last follow-up date

2016 Year 02 Month 10 Day

Date of closure to data entry

2016 Year 04 Month 13 Day

Date trial data considered complete

2016 Year 04 Month 20 Day

Date analysis concluded

2016 Year 11 Month 17 Day


Other

Other related information



Management information

Registered date

2015 Year 10 Month 22 Day

Last modified on

2017 Year 10 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022406


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name